Vera Therapeutics (VERA) stock jumped 4% after two-year ORIGIN3 trial data showed Trutakna slowed kidney decline to normal aging rates in IgAN patients. The post Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results appeared first on Blockonomi.